CN105682657A - 包含透明质酸和甲哌卡因的组合物 - Google Patents

包含透明质酸和甲哌卡因的组合物 Download PDF

Info

Publication number
CN105682657A
CN105682657A CN201480054186.7A CN201480054186A CN105682657A CN 105682657 A CN105682657 A CN 105682657A CN 201480054186 A CN201480054186 A CN 201480054186A CN 105682657 A CN105682657 A CN 105682657A
Authority
CN
China
Prior art keywords
hyaluronic acid
salt
mepivacaine
compositions
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480054186.7A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗索瓦·鲍登
史蒂芬·默尼耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teoxane SA
Original Assignee
Teoxane SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51570796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105682657(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teoxane SA filed Critical Teoxane SA
Priority to CN202110975571.7A priority Critical patent/CN113648459A/zh
Publication of CN105682657A publication Critical patent/CN105682657A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480054186.7A 2013-07-30 2014-07-29 包含透明质酸和甲哌卡因的组合物 Pending CN105682657A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110975571.7A CN113648459A (zh) 2013-07-30 2014-07-29 包含透明质酸和甲哌卡因的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/954,360 US9421198B2 (en) 2013-07-30 2013-07-30 Composition comprising hyaluronic acid and mepivacaine
US13/954,360 2013-07-30
PCT/IB2014/063503 WO2015015407A1 (en) 2013-07-30 2014-07-29 Composition comprising hyaluronic acid and mepivacaine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110975571.7A Division CN113648459A (zh) 2013-07-30 2014-07-29 包含透明质酸和甲哌卡因的组合物

Publications (1)

Publication Number Publication Date
CN105682657A true CN105682657A (zh) 2016-06-15

Family

ID=51570796

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480054186.7A Pending CN105682657A (zh) 2013-07-30 2014-07-29 包含透明质酸和甲哌卡因的组合物
CN202110975571.7A Pending CN113648459A (zh) 2013-07-30 2014-07-29 包含透明质酸和甲哌卡因的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110975571.7A Pending CN113648459A (zh) 2013-07-30 2014-07-29 包含透明质酸和甲哌卡因的组合物

Country Status (21)

Country Link
US (9) US9421198B2 (enExample)
EP (2) EP3574901B1 (enExample)
JP (1) JP6543625B2 (enExample)
KR (2) KR20160038047A (enExample)
CN (2) CN105682657A (enExample)
AU (1) AU2014298046B2 (enExample)
BR (1) BR112016002171A2 (enExample)
CA (1) CA2919792C (enExample)
CY (1) CY1122648T1 (enExample)
DK (2) DK3574901T3 (enExample)
ES (2) ES2910519T3 (enExample)
HR (1) HRP20191345T1 (enExample)
HU (1) HUE045969T2 (enExample)
LT (1) LT3027186T (enExample)
PL (2) PL3027186T3 (enExample)
PT (2) PT3574901T (enExample)
RS (1) RS59108B1 (enExample)
RU (1) RU2670617C2 (enExample)
SI (1) SI3027186T1 (enExample)
SM (1) SMT201900494T1 (enExample)
WO (1) WO2015015407A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110721142A (zh) * 2018-07-17 2020-01-24 上海美白臻生物科技有限公司 一种全效型微整专用玻尿酸制备工艺
CN111787915A (zh) * 2017-04-12 2020-10-16 尤里根制药股份有限公司 注射器中包含局部麻醉剂、缓冲剂和糖胺聚糖的稳定性提高的制品
CN111787966A (zh) * 2017-12-19 2020-10-16 大化制药株式会社 包含局部麻醉药和透明质酸水凝胶的预填充式注射器的制造方法
CN113546539A (zh) * 2020-04-24 2021-10-26 透策生技股份有限公司 利用加压手段以加速注射式填充物分散的处理方法
CN117357699A (zh) * 2022-07-06 2024-01-09 渼颜空间(河北)生物科技有限公司 一种具有祛斑功效的透明质酸钠组合物及其制备方法和其应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
FR3015290B1 (fr) * 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
FR3036035B1 (fr) 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
EP3165233B1 (en) * 2015-08-28 2021-08-18 Latvijas Universitate Biomaterial for treatment of acute and chronic skin wounds
FR3058064B1 (fr) 2016-10-28 2020-08-07 Lab Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaine
EP3354258A1 (en) * 2017-01-31 2018-08-01 Teoxane SA Use of a cohesive gel as a matrix material in a periodontal pocket
US11123455B2 (en) * 2017-02-28 2021-09-21 Cg Bio Co., Ltd. Composition for dermal injection
EP3731808B1 (en) * 2017-12-29 2023-09-20 Matex Lab S.P.A. Method to prepare filler with a hyaluronic acid base comprising a neutralization step
CN112118849A (zh) * 2018-02-06 2020-12-22 瑞珍实验室 交联透明质酸及与prp/bmc的组合
KR102334794B1 (ko) * 2018-12-20 2021-12-03 주식회사 엘지화학 우수한 필러 특성을 갖는 히알루론산 하이드로겔을 포함하는 필러
WO2020232539A1 (en) 2019-05-17 2020-11-26 The Governing Council Of The University Of Toronto Sustained release local anesthetic hydrogel composition
US12414917B2 (en) 2019-09-13 2025-09-16 University Of Utah Research Foundation Opioid independent surgical anesthetic
FR3105729B1 (fr) * 2019-12-31 2023-07-21 Mrs Biotech Composition pour la gestion du poids d’un sujet
EP3861996A1 (en) 2020-02-04 2021-08-11 I+Med S. Coop. Controlled release system of phytocannabinoids formulations soluble in aqueous media, methods and uses thereof
EP4199980A1 (en) * 2020-08-18 2023-06-28 Innate S.r.l. Injectable composition and use of said composition
CN113896915B (zh) * 2021-11-10 2024-02-13 爱美客技术发展股份有限公司 一种凝胶材料及其制备方法与应用
KR20240105428A (ko) * 2021-11-10 2024-07-05 아이메이커 테크놀러지 디벨롭먼트 캄파니 리미티드 겔 재료 및 이의 제조 방법과 응용
KR102451308B1 (ko) * 2022-02-21 2022-10-07 이광미 금속 티오옥토일 히알루로네이트 복합체 및 이의 제조 방법
WO2023158281A1 (ko) * 2022-02-21 2023-08-24 이광미 금속 티오옥토일 히알루로네이트 복합체 및 그의 용도
KR102559788B1 (ko) * 2022-04-21 2023-07-27 주식회사 티앤알바이오팹 다단계 탈세포화된 조직 매트릭스 및 이의 제조방법
CN115737506B (zh) * 2022-12-16 2023-09-05 江苏亨瑞生物医药科技有限公司 一种含有胶原蛋白的面膜及其制备方法
KR102680817B1 (ko) * 2023-06-02 2024-07-03 주식회사 에스씨엘 히알루론산 필러의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1893989A (zh) * 2003-12-22 2007-01-10 安尼卡医疗有限公司 用于组织填充的交联透明质酸
WO2012104419A1 (en) * 2011-02-03 2012-08-09 Q-Med Ab Hyaluronic acid composition
FR2979539A1 (fr) * 2011-09-05 2013-03-08 Teoxane Composition sterile dermo-injectable

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799679A (en) 1955-04-28 1957-07-16 Bofors Ab Process of preparing amides of heterocyclic carboxylic acids
GB826668A (en) 1955-06-27 1960-01-20 Crookes Lab Ltd Process for manufacturing basic carboxamides
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
DE10246340A1 (de) 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
AU2004312532B2 (en) 2003-12-30 2010-05-20 Genzyme Corporation Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
CA2554190A1 (en) 2004-01-23 2005-08-04 Ohio University Pgg separation and purification
JP4875988B2 (ja) * 2004-11-15 2012-02-15 株式会社 資生堂 架橋ヒアルロン酸ゲルの製造方法
US8092730B2 (en) 2005-12-06 2012-01-10 Entegris, Inc. Molded rotatable base for a porous pad
KR20110037979A (ko) 2008-05-30 2011-04-13 알러간, 인코포레이티드 액체 상태 또는 젤 상태의 연조직 증대 필러, 생활성 제제 및 기타 생체적합성 물질을 위한 주사 장치
US8357795B2 (en) * 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
FR2945293B1 (fr) 2009-05-11 2011-06-17 Teoxane Procede de preparation d'un gel reticule.
US9050246B2 (en) * 2009-05-29 2015-06-09 Galderma Research & Development Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
US20110171286A1 (en) 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
FR2962040B3 (fr) * 2010-07-05 2012-08-10 Alain Villette Composition injectable comprenant un medicament injectable et un gel
NZ708247A (en) 2010-11-08 2017-01-27 Allergan Ind Sas Hyaluronic acid based formulations
EP2606828B1 (en) 2011-12-20 2018-04-11 Angioclinic AG Hyaluronic acid and its use for treating venous insufficiency and varicose veins
US9241921B2 (en) * 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
AU2012262047A1 (en) * 2011-06-03 2014-01-16 Allergan, Inc. Dermal filler compositions including antioxidants
US20130131632A1 (en) 2011-11-18 2013-05-23 Allergan, Inc. Injection device and method for diluting an injectable fluid
FR2991876B1 (fr) * 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
CN102805882B (zh) * 2012-08-28 2014-04-23 华熙福瑞达生物医药有限公司 一种软组织填充剂在使用前与麻醉剂注射液混合的方法
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
WO2014093645A2 (en) * 2012-12-13 2014-06-19 Precision Dermatology, Inc. Topical formulations for increasing the dermal concentration of hyaluronic acid
WO2014165113A1 (en) 2013-03-12 2014-10-09 Allergan Holdings France S.A.S. Cross-linked hyaluronic acid threads for treatment of striae
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
FR3015290B1 (fr) 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1893989A (zh) * 2003-12-22 2007-01-10 安尼卡医疗有限公司 用于组织填充的交联透明质酸
WO2012104419A1 (en) * 2011-02-03 2012-08-09 Q-Med Ab Hyaluronic acid composition
FR2979539A1 (fr) * 2011-09-05 2013-03-08 Teoxane Composition sterile dermo-injectable

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111787915A (zh) * 2017-04-12 2020-10-16 尤里根制药股份有限公司 注射器中包含局部麻醉剂、缓冲剂和糖胺聚糖的稳定性提高的制品
CN111787966A (zh) * 2017-12-19 2020-10-16 大化制药株式会社 包含局部麻醉药和透明质酸水凝胶的预填充式注射器的制造方法
CN110721142A (zh) * 2018-07-17 2020-01-24 上海美白臻生物科技有限公司 一种全效型微整专用玻尿酸制备工艺
CN113546539A (zh) * 2020-04-24 2021-10-26 透策生技股份有限公司 利用加压手段以加速注射式填充物分散的处理方法
CN117357699A (zh) * 2022-07-06 2024-01-09 渼颜空间(河北)生物科技有限公司 一种具有祛斑功效的透明质酸钠组合物及其制备方法和其应用

Also Published As

Publication number Publication date
BR112016002171A2 (pt) 2017-08-01
US9925309B2 (en) 2018-03-27
US9789226B2 (en) 2017-10-17
PL3574901T3 (pl) 2022-05-09
LT3027186T (lt) 2019-09-10
US9421198B2 (en) 2016-08-23
KR20210110406A (ko) 2021-09-07
US20200390940A1 (en) 2020-12-17
US10322212B2 (en) 2019-06-18
US9498562B1 (en) 2016-11-22
EP3574901A1 (en) 2019-12-04
RU2016106152A (ru) 2017-08-31
US20180169304A1 (en) 2018-06-21
US20160166554A1 (en) 2016-06-16
KR20160038047A (ko) 2016-04-06
US20220362439A1 (en) 2022-11-17
US20180021480A1 (en) 2018-01-25
SMT201900494T1 (it) 2019-11-13
US20160325021A1 (en) 2016-11-10
EP3574901B1 (en) 2022-01-26
DK3574901T3 (da) 2022-03-07
US20190184065A1 (en) 2019-06-20
US10413637B2 (en) 2019-09-17
ES2743755T3 (es) 2020-02-20
SI3027186T1 (sl) 2019-09-30
US10786601B2 (en) 2020-09-29
JP6543625B2 (ja) 2019-07-10
CY1122648T1 (el) 2021-05-05
CA2919792A1 (en) 2015-02-05
RS59108B1 (sr) 2019-09-30
JP2016527264A (ja) 2016-09-08
AU2014298046A1 (en) 2016-03-10
ES2910519T3 (es) 2022-05-12
RU2670617C2 (ru) 2018-10-24
DK3027186T3 (da) 2019-09-16
CN113648459A (zh) 2021-11-16
CA2919792C (en) 2020-01-28
US11406738B2 (en) 2022-08-09
PT3574901T (pt) 2022-04-08
PT3027186T (pt) 2019-09-09
US20150038457A1 (en) 2015-02-05
HRP20191345T1 (hr) 2019-11-01
EP3027186B1 (en) 2019-06-19
EP3027186A1 (en) 2016-06-08
PL3027186T3 (pl) 2019-12-31
US20180318469A1 (en) 2018-11-08
WO2015015407A1 (en) 2015-02-05
HUE045969T2 (hu) 2020-01-28
AU2014298046B2 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
US11406738B2 (en) Composition comprising hyaluronic acid and mepivacaine
JP6521862B2 (ja) 皮膚用の注入可能な滅菌組成物
JP6446462B2 (ja) メピバカインを含有するヒアルロン酸組成物
JP2013544583A (ja) ヒアルロン酸ベースの製剤
JP2011529762A5 (enExample)
JP2021058615A (ja) 顎先等の顔面の容貌を造形し、拡張し、または補正するためのインプラント
CN104582672A (zh) 包含至少一种透明质酸和抗坏血酸磷酸酯镁的经灭菌组合物
KR20180004256A (ko) 적어도 하나의 폴리올 및 적어도 하나의 마취제를 포함하는 조성물
CN111132705A (zh) 一种含有交联透明质酸以及阿替卡因的无菌注射用组合物
RU2779473C1 (ru) Наполнитель, имеющий прекрасные свойства наполнителя, содержащий гидрогель гиалуроновой кислоты
WO2016132167A1 (en) Implants for sculpting, augmenting or correcting facial features such as the chin
HK1238179B (zh) 包含至少一种透明质酸和抗坏血酸磷酸酯镁的经灭菌组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160615

RJ01 Rejection of invention patent application after publication